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Abstract
A 54-year-old woman was diagnosed with infiltrative ductal breast carcinoma. Two years after treatment, the
patient developed an acute myeloid leukemia (AML) which harbored del(11q23) in 8% of the blast cells. The
patient was submitted for allogeneic stem cell transplantation (aSCT) from her HLA-compatible sister. Ten months
after transplantation, she relapsed with an AML with basophilic maturation characterized by CD45
low CD33
high,
CD117
+, CD13
-/+, HLA Dr
high, CD123
high, and CD203c
+ blast cells lacking expression of CD7, CD10, CD34, CD15,
CD14, CD56, CD36, CD64, and cytoplasmic tryptase. Karyotype analysis showed the emergence of a new clone with
t(2;14) and FISH analysis indicated the presence of MLL gene rearrangement consistent with del(11q23).
Interestingly, AML blast cell DNA tested with microsatellite markers showed the same pattern as the donor’s,
suggesting that this AML emerged from donor cells. Additionally, polymorphisms of the XPA, XPD, XRCC1, XRCC3
and RAD51 DNA repair genes revealed three unfavorable alleles with low DNA repair capacity.
In summary, we report the first case of AML involving XPD and XRCC3 polymorphisms from donor origin following
allogeneic stem cell transplantation and highlight the potential need for careful analysis of DNA repair gene
polymorphisms in selecting candidate donors prior to allogeneic stem cell transplantation.
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Background
Breast cancer is the most frequent malignancy in women
[1]. Over recent decades overall survival of breast cancer
patients has increased considerably as a result of earlier
diagnosis and increasing use of adjuvant therapies [2,3].
Nevertheless, the risk of developing a secondary cancer
increases as a long-term complication related to the use
of cytotoxic DNA-targeted antiproliferative drugs and
hormone therapy with or without radiotherapy [4,5].
Among other complications, a small proportion of all
breast cancer survivors subsequently develop acute
myeloblastic leukemia (AML), preceded or not by a pre-
leukemic myelodysplastic syndrome (MDS) [5]. Second-
ary AML has many morphological and cytogenetic
variants because transforming mutations leading to the
disease are heterogeneous and occur in an early multipo-
tential hematopoietic cell that retains the potential to dif-
ferentiate into virtually every hematopoietic lineage [6].
Here we report a rare case of a donor-related second-
a r yA M Lw i t hb a s o p h i l i cm a t uration post-allogeneic
stem cell transplantation in a patient with prior history
of secondary AML derived from primary breast cancer
chemotherapy. To our knowledge this is the first case
reported in the literature of a donor cell-derived AML
secondary to breast cancer treatment and allogeneic
stem cell transplantation associated with unfavourable
DNA repair gene polymorphisms.
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A 54-year-old woman was submitted for mastectomy in
May 2004 because of an infiltrative ductal breast carci-
noma, with negative nodal infiltration and without expres-
sion of hormone receptors. After surgery, she was treated
with cyclophosphamide (600 mg/m
2) and doxorubicin (60
mg/m
2; 4 cycles) followed by adjuvant radiotherapy. In
December 2006, the patient presented with fever, anemia,
and gingival bleeding. Peripheral blood data revealed ane-
mia (hemoglobin level of 7.7 g/L) and thrombocytopenia
(12 × 10
9 platelets/L) with an increased white blood cell
count (35.4 × 10
9 leucocytes/L), with 70% blasts. A bone
marrow aspirate sample showed diffuse infiltration by
blast cells and diagnosis of AML M5 according to the
French-American-British (FAB) classification was made.
On immunophenotypic criteria, blast cells were positive
for CD33, CD117, CD13, and HLA-DR.
Cytogenetic studies performed on a bone marrow aspi-
rate sample using standard culture methods and GTG
banding revealed a normal 46, XX[25] karyotype at the
time of the diagnosis of secondary AML prior to allogeneic
stem cell transplantation (allo-SCT). Cytogenetic markers
for secondary AML [del(11)(q23), del(5q)/-5 or del(7q)/-7]
were further investigated by interphase fluorescence in situ
hybridization (iFISH) using the LSI MLL (11q23) dual
color, LSI D7S486 spectrum orange/CEP7 spectrum green,
LSI EGR1 spectrum orange/LSID5S23:D5S721 spectrum
green, and LSI CSF 1R spectrum orange/LSID5S23:D5S721
spectrum green (Vysis, Abbott Laboratories, USA) iFISH
probes and showed 8% cells carrying del(11q23) in the
absence of abnormalities of both chromosomes 5 and 7.
The patient was treated with AraC and idarrubicin [7-9]
and complete remission was attained. Consolidation was
performed with cytarabin-arabinose (high dose Ara-C) plus
filgrastin, as prophylaxis for leucopenia.
After two cycles of consolidation, she was submitted
to an allo-SCT from her HLA-compatible sister. The
conditioning regimen for the allo-SCT consisted of bus-
sulfan and cyclosphosphamide. At day +48, she devel-
oped acute graft versus host disease (aGVHD), and was
treated with corticosteroids and cyclosporine (CSA). At
day +280, an inguinal 4 × 3 cm mass appeared and the
presence of malignant cells was revealed upon biopsy.
At day +300, a bone marrow aspirate showed 50%
blasts. Cellular and molecular analyses were performed
in parallel on this sample. Immunophenotyping of bone
marrow cells confirmed the presence of CD45
low
CD33
high, CD117
+, CD13
-/+, HLA Dr
high CD123
high blast
cells, lacking expression of CD7, CD10, CD34, CD15,
CD14, CD56, CD36, and CD64 (Figure 1A-F),
Figure 1 Bivariate flow cytometry dot plots showing the immunoreactivity pattern of blast cells (gated on CD45 vs. SSC) for CD45
low =
25% (panel A), CD33 = 24% (panel B), CD117 = 24% (panel C), CD13 = 16% (panel D), HLA-DR = 25% (panel E), and CD123 = 25%(panel F).
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lineages. Further immunocytochemical stainings were
performed showing CD203c expression in the absence
of cytoplasmic tryptase (Figure 2A and 2B); these
together with the high expression for CD123 were con-
sistent with basophilic maturation.
Microsatellite and PCR-RFLP analyses were performed
on genomic DNA from mononuclear cells of the patient
pre-transplant, of the AML blast cell sample obtained
after transplantation, and of the donor bone marrow
cells. The 11 tested microsatellite markers are often
used in forensic medicine for individual identification.
As displayed in Table 1, 7 of the analyzed loci (D21S11,
D7S820, CSF1PO, D3S1358, Vwa, D13S317, and TPOX)
were informative and showed the coincidence of profile
between AML blasts after transplantation and the
donor’s cells, supporting full engraftment of the stem
cell transplant as well as the donor cell-origin of the
AML blasts.
Genetic polymorphisms of five relevant human DNA
repair genes (XPA, XPD, XRCC1, XRCC3,a n dRAD51)
were further analyzed by PCR-RFLP [10-15] on the sec-
ondary AML blast DNA and compared to a pre-trans-
plant DNA sample from the patient and to DNA from
the donor. Analysis of leukemia-prone polymorphic
alleles (XPA A23G, XPD Lys751Gln, XRCC1 Arg399Gln,
XRCC3 Thr241Met, and RAD51 G135C) revealed an
XPD and XRCC3-deficient heterozygous pre-SCT
patient with normal alleles for XPA, XRCC1,a n d
RAD51 DNA repair functions (Table 2 and Figure 3).
Donor polymorphisms were different, harboring both
XPD- and XRCC3-deficient homozygosis. Once microsa-
tellite analysis indicated post-transplant total chimerism,
post-SCT patient cells were shown to have acquired the
genotypic markers of the donor’s poorer DNA repair
functions (Table 2 and Figure 3).
The patient was then treated with idarubicin, cytosine
arabinoside (ARA-C) with no response. At that time the
immunophenotypic study showed the same profile, but
conventional cytogenetics revealed the emergence of a
new clone: 46, XX, t(2;14)(q37;q22)[2]/46, XX [33](Fig-
ure 4). Treatment was modified and FLAG [fludarabin,
ARA-C, and granulocyte colony-stimulating factor (G-
CSF)] was started. After 18 days the patient had hema-
topoietic recovery with 3% blasts. Twenty-one days after
FLAG, a donor lymphocyte infusion (DLI) was given,
which was followed by GVHD, and the patient was trea-
ted with corticosteroids. The patient was submitted to a
second DLI four months later. At day +14 after this sec-
ond DLI, the karyotype post-DLI was normal, 46, XX
[43], but FISH analysis indicated the presence of MLL
gene rearrangements consistent with del(11q23) in 5%
of the cells. The myelogram showed 62% blasts. Rescue
therapy with high dose topotecan and ARA-C was
started and administered for five days without haemato-
logic response; peripheral blood infiltration by blast cells
rose to 80% after 14 days. Palliative support began and
the patient died after 17 months of stem cell infusion.
Discussions and Conclusions
Here we report a case of a secondary AML developing
from donor-derived cells in a breast cancer patient who
underwent allogeneic stem cell transplantation. Donor
cell leukemia is a rare although well-recognized disease
entity following SCT that occurs as the result of onco-
genic transformation of apparently normal donor hema-
topoietic cells in the transplant recipient.
Many studies have reported an increased risk of breast
cancer patients to develop leukemia after chemotherapy,
radiotherapy and G-CSF administration [1,5,16,17].
Because of this, risk estimates on the eventual develop-
ment of post-treatment AML/MDS have to be cast
when deciding a patient’s treatment. In these studies,
Figure 2 Bone marrow smear after allo-SCT relapse. A- Note the
presence of basophils with CD203c
+in the sample with
approximately 20% of blasts being CD203c
+. B- Note the absence of
tryptase staining.
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treated with alkylating agents and anthracyclines. Post-
treatment secondary leukemias associated with prior
administration of alkylating agents (e.g., cyclophospha-
mide) typically differ from those arising after treatment
with DNA topoisomerase II inhibitors, such as anthracy-
clines. Accordingly, AML’s developing after topoisome-
rase II inhibitors are given typically show an early onset,
and display monocytic and myelomonocytic features in
association with abnormalities of chromosomes 11 and
21 (especially balanced translocations involving the
11q23 and 21q22 regions). Whereas those arising after
treatment with alkylating agents frequently show neutro-
phil/granulocytic maturation together with abnormalities
of chromosome 5 and 7. These changes are seen in the
absence of chromosomal translocations and the leuke-
mias emerge much later after therapy [18].
Exposure to radiotherapy may further increase the risk
for AML [19-21]. In turn, Smith et al. [20] found the
M4/M5 subtypes to be more frequent in patients receiv-
ing intense treatment regimens and concluded that this
could be the result of cyclophosphamide-induced pro-
motion of a doxorubicin-associated leukemogenic effect.
In the case reported here, the association of chemother-
apy and radiotherapy protocols most probably played a
role in the development of AML. Secondary AML out-
comes are thus believed to arise from genomic instabil-
ity (i.e., deletions, mutations, translocations) induced by
therapy-associated DNA damage [22,23]. Two different
hypotheses remain which could contribute to explain
the development of secondary AML: a truly stochastic
event, or individual differences on cancer susceptibility
[22]. The latter appears to better explain the case
reported here. In this regard, previous reports have
described polymorphisms conferring sensitivity to che-
motherapy, which may contribute to the incidence of
secondary AML outcomes [24-26]. Alternatively, it is
possible that germline variations in DNA repair genes
may also enhance the risk of therapy-induced secondary
AML in patients carrying DNA-repair deficient genes
[27]. In fact it has also been shown that single nucleo-
tide polymorphisms (SNP) in DNA repair genes may
code malfunctioning proteins, in association with an
increased predisposition to cancer and the response of
leukemia patients following chemotherapy [12,28,29].
Here we investigated five alleles of DNA repair genes
already ascribed to susceptibility to leukemia (XRCC1,
XPA, XPD, XRCC3 and RAD51). As expected, poly-
morphic alleles found by genotyping in both the patient
Table 1 Microsatellite markers in the patient’s pre and
post-transplant haematopoietic cells compared with the
donor’s
Marker Patient pre-SCT Patient AML Donor
D21S11 28 28 28
31.2 29 29
D7S820 8 88
10 99
CSF1PO 11 88
12 11 11
D3S1358 15 15 15
15 17 17
TH01 8 8 8
99 9
D13S317 9 11 11
13 13 13
D16S539 13 13 13
14 14 14
Vwa 16 17 17
18 18 18
TPOX 8 99
11 12 12
D5S818 12 12 12
13 13 13
FGA 21 21 21
23 23 23
Informative and coincident markers are identified in bold.
Table 2 DNA repair polymorphisms in the patient’s pre- and post-transplantation (AML) cells and donor’s cells
Polymorphism DNA repair
mechanism
Patient cells (pre-
transplantation)
AML cells (post-
transplantation)
Donor cells
XPA A23G NER Homozygous for optimal DRC Homozygous for optimal DRC Homozygous for optimal DRC
XPD Lys751Gln NER Heterozygous deficient DRC Homozygous for deficient DRC Homozygous for deficient
DRC
XRCC1 Ar399Gln BER Homozygous for optimal DRC Homozygous for optimal DRC Homozygous for optimal DRC
XRCC3
Thr243Met
HRR Heterozygous for deficient DRC Homozygous for deficient DRC Homozygous for deficient
DRC
RAD51 G135C HRR Homozygous for optimal DRC Homozygous for optimal DRC Homozygous for optimal DRC
DRC - DNA repair capacity
NER - Nucleotide Excision Repair
BER - Base Excision Repair
HRR - Homologous Recombination Repair
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the same, revealing successful transplant, which could
also explain the otherwise observed resistance to treat-
ment and clinical evolution. In turn, pre-SCT patient
cells were heterozygous for allelic variants in the XPD
and XRCC3 genes that are associated with lower repair
capacity, conspicuously bearing on susceptibility to
breast cancer and chemotherapy-related leukemia
(AML) in this patient. Consistent with our observations,
Allan et al. [12] showed that individuals carrying at least
one XPD- Lys751Gln allele were more likely to have an
adverse prognosis following chemotherapy. The XPD
Gln751 polymorphic protein was shown to fail in enga-
ging apoptosis in chemotherapy-damaged cells, thus
avoiding elimination of mutated myeloid precursors. In
order to search for an association of the poor outcome
Figure 3 RFLP analysis of DNA generated by digestion of XPA (3A), XPD (3B), XRCC1 (3C), XRCC3 (3D), and RAD51 (3E) PCR products
digested with or without their specific RFLP diagnostic restriction enzymes. M = 50 bp ladder marker; Lane 1 = non-digested PCR
amplification of normal allele; Lane 2 = digestion pattern from the positive control K562 myeloid cell line alleles; Lane 3 = digestion pattern
from patient alleles before transplantation; Lane 4 = digestion pattern from patient alleles from AML cell DNA after transplantation; Lane 5 =
digestion pattern from donor cell alleles.
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gene set of polymorphisms was screened for in the
donor’s DNA. Remarkably, donor DNA genotyped
homozygous not only for the XPD (Lys751Gln) subopti-
mal allele, but also for the XRCC3-deficient allele
(Thr243Met). Both post-SCT blast cells and donor DNA
were coincident in XPD-a n dXRCC3-deficient homo-
zygosity, supporting a donor origin for the leukemic
blasts.
The XRCC3 protein plays a critical role in Homolo-
gous Recombination Repair (HRR) accounting for repair
of DNA double-strand breaks (DSB). Whenever it is
deficient, unsealed or misrepaired breaks can generate
oncogenic chromosomal translocations. When found
together, allelic variants in Lys751Gln XPD and
Thr241Met XRCC3 polymorphisms have been asso-
ciated with both a worse repair capacity and resistance
to apoptosis [11,30]. Once introduced into the patient’s
drug-intoxicated bone marrow, disrupted DNA repair
and apoptosis pathways in the donor’sc e l l sm a yh a v e
accumulated unrepaired damages while escaping apop-
tosis, thus boosting aggressiveness. Indeed, this is
further supported by the observation of a switch from
normal to highly abnormal post-SCT of the patient’s
karyotype and FISH analysis. This supports the theory
that in donor origin leukemia, the host environment in
which the original malignancy developed could trigger
an oncogenic process in donor cells, favored by the
immunosuppressive status after transplantation, espe-
cially because the donor is still healthy [31,32].
An additional interesting finding is the maturation
observed phenotypically towards the basophilic versus
mast cell lineages based on coexpression of CD203c and
both CD123, CD117 [33]. Cases of de novo AML with
predominant basophilic and/or mastocytic, cell pheno-
types are uncommon and they account for only 4-5% of
all cases of acute nonlymphocytic leukemia [34,35].
Although acute basophilic leukemia (ABL) has been
long diagnosed as such, current knowledge of this speci-
fic AML subtype remains limited [36].
In conclusion, here we describe a very rare case of
donor origin AML from a sibling who harbored germline
XPD and XRCC3 homozygous polymorphisms in a breast
cancer patient following chemotherapy. The blasts
showed SNP profiles of the donor including susceptible
alleles for unfavorable genotypes in DNA repair genes.
Determination of the donor’s DNA repair genotype, cap-
able of stimulating genetic instability in a diseased recipi-
ent, could be important for future transplantation
procedures and therefore should be investigated further.
DNA repair mechanisms are responsible for maintenance
of the genome integrity avoiding additional mutations in
key cell cycle regulation genes which are responsable for
“leukemization”. To ensure that DNA repair mechanisms
are properly working, more donor cell gene polymorph-
isms or mutations should be studied. After the interpre-
tation of results, a reference panel of low DNA repair
capacity polymorphisms or mutations should be included
in the international guidelines for screening donor DNA
before SCT.
Figure 4 Illustrating metaphase (G-banding) of AML cells obtained after initial therapy of AML: 46, XX, t(2;14)(q37;q22)[2]/46, XX[33].
Arrows denote the chromosomes assumed to be involved in t(2;14)(q37;q22).
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